Restless legs syndrome.

Ilia Itin; Cynthia L Comella

doi:10.1016/j.pop.2005.02.008

Home/Archive/PubMed

PubMed · 15935194

Restless legs syndrome.

Ilia Itin·Cynthia L Comella

View original source ↗Export metadata ↓

Abstract

RLS is a common condition that is likely to be encountered by primary care physicians in their practice. The currently available medications are highly effective in treating RLS. The knowledge of clinical presentation and diagnostic features of RLS will empower the primary care practitioners to effectively treat their patients who have RLS.

Explore related subjects

Dopamine Agonists Humans Iron Primary Health Care Restless Legs Syndrome Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Ilia Itin, Cynthia L Comella. 2005. Restless legs syndrome.. https://doi.org/10.1016/j.pop.2005.02.008

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.

Explore the source record for details and available documents.

Dopamine Agonists↗

PubMed2006

Dopamine agonists and pathological gambling.

Explore the source record for details and available documents.

Dopamine Agonists↗

PubMed2006

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

Prolactinomas are the more prevalent functioning pituitary tumors, and dopamine agonist drugs (DA) are the main therapeutic option for patients harboring such tumors. Bromocriptine (BRC) resistance, defined as failure to normalize prolactin (PRL) and/or to shrink the tumor is reported in 5 to 18% of the patients treated with this drug, the first DA widely used. Cabergoline (CBG) can bring PRL to normalization and reduce tumor size in up to 86% and 92% of the patients, respectively. Even with this newer DA, a subset of patients does not respond to therapy and are truly resistant. The mechanisms for resistance are not yet fully clarified, so the treatment for the resistant prolactinoma is still a challenge. Transsphenoidal surgery associated or not to radiotherapy is an important tool, but PRL may not normalize, mainly in macroprolactinomas. Treatment with sex steroids or ovulation induction can solve the hypogonadism or infertility, when the tumor growth is under control. New drugs as anti-estrogens, new DA, specific analogs for somatostatin receptor subtypes, chimeric molecules associating dopamine and somatostatin effect, and PRL antagonists are under investigation and can be future alternatives for DA resistance.

Dopamine Agonists↗